This multicentre study evaluated 5-year progression-free (PFS) and overall survival (OS) in early and advanced Hodgkin lymphoma (HL), where therapy was individualized based on initial prognostic factors and positron emission tomography-computed tomography performed after two cycles (PET-2). Between September 2006 and August 2013, 359 patients aged 18-60 years, were recruited in nine Israeli centres. Early-HL patients initially received ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) 92. Depending on initial unfavourable prognostic features, PET-2-positive patients received additional ABVD followed by involved-site radiotherapy (ISRT). Patients with negative PET-2 and favourable disease received ISRT or ABVD 92; those with unfavourable disease received ABVD 92 with ISRT or, alternatively, ABVD 94. Advanced-HL patients initially received ABVD 92 or escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone; EB) 92 based on their international prognostic score (≤2 or ≥3). PET-2-negative patients further received ABVD 94; PET-2-positive patients received EB 94 and ISRT to residual masses. With a median follow-up of 55 (13-119) months, 5-year PFS was 91% and 69% for PET-2-negative and positive early-HL, respectively; 5-year OS was 100% and 95%, respectively. For advanced-HL, the PFS was 81% and 68%, respectively (P = 0Á08); 5-year OS was 98% and 91%, respectively. PET-2 positivity is associated with inferior prognosis in early-HL, even with additional ABVD and ISRT. Advanced-HL patients benefit from therapy escalation following positive PET-2. EB can be safely de-escalated to ABVD in PET-2-negative patients.
2015) or recently published (Raemaekers et al, 2014; Casasnovas et al, 2015; Friedberg et al, 2016; Johnson et al, 2016; Zinzani et al, 2016) .
This study aimed to prospectively evaluate the 5-year PFS and OS of patients with HL whose initial therapy was based on pre-treatment prognostic factors, then tailored in an individualized manner according to results of PET/CT imaging performed after two cycles of chemotherapy (PET-2).
Patients and methods
This is a prospective multicentre trial approved by Institutional Review Boards of all participating centres and registered at ClinicalTrials.gov (NCT00392314). After providing written informed consent, eligible patients with classic HL (age 18-60 years, stages I-IV) were recruited between September 2006 and August 2013. Prior to chemotherapy, all patients underwent staging PET/CT, pulmonary function testing and echocardiography; women aged <40 years were offered gonadotropin-releasing hormone (GNRH) agonist or other fertility-preserving procedures; men underwent sperm preservation.
Patients with early HL (stages IA-IIA) were categorized into early favourable (EF-HL) and unfavourable (EUF-HL) based on the presence of ≥1 of the following factors: extra-nodal disease, bulky mediastinal mass >10 cm, erythrocyte sedimentation rate >50, ≥3 disease sites, and age ≥50 years, based on modified European Organization for Research and Treatment of Cancer (EORTC) and German Hodgkin Study Group (GHSG) criteria. Patients with advanced disease (B symptoms or stages III/IV) were allocated to initial therapy according to their baseline International Prognostic Score (IPS): IPS 0-2 and IPS 3-7 (Hasenclever & Diehl, 1998) .
Therapeutic protocol
Patients with EF-HL received two ABVD cycles (adriamycin, bleomycin, vinblastine, dacarbazine) (Box S1); PET-2-negative patients underwent involved site radiation therapy (ISRT) at a dose of 25-30 Gy, while PET-2-positive patients received two additional ABVD courses (total 4) followed by ISRT. Patients with EUF-HL initially received two ABVD cycles; those with negative PET-2 scans received two additional ABVD cycles followed by ISRT, while those with positive scans received four additional ABVD cycles (total 6) followed by . At the treating physician's discretion, patients with negative PET-2, with multiple or extensive disease sites or fields overlapping breast tissue (women), could forego radiotherapy and receive two further courses of ABVD instead (Fig 1) .
Advanced-HL patients with IPS 0-2 initially received two ABVD cycles and those with IPS ≥3 initially received two cycles of escalated BEACOPP (EB) (Diehl et al, 2003) (Box S2). If PET-2 was negative, therapy was completed with four ABVD cycles. If PET-2 was positive without evidence of disease progression, EB was continued (total 6 cycles), with ISRT given to residual masses. Patients progressing during the study were withdrawn and received salvage therapy.
Study endpoints
The primary endpoint was the 5-year PFS, measured from date of chemotherapy initiation to the date of disease relapse/progression or death from any cause (Cheson et al, 2007) . Secondary outcomes included OS, toxicity, dose intensity, restoration of menstrual function and pregnancy. Response to therapy and PFS were assessed in subgroups Treatment schema used in the current study. *Steroid administration for 8 days only to minimize bone toxicity. Ad-HL, advancedstage Hodgkin lymphoma; E-HL, early-stage Hodgkin lymphoma; EF-HL, early favourable Hodgkin lymphoma; EUF-HL, early unfavourable Hodgkin lymphoma; IPS, International Prognostic Score; MM-Mediastinal Mass; PET-2, positron emission tomography-computed tomography performed after two cycles of therapy receiving/not receiving radiotherapy and with/without bulky disease (defined as a mass >10 cm in size). Dose intensity was expressed as percentage of the designed dose (Evens et al, 2007) .
PET/CT evaluations
PET/CT was performed at baseline, 10-14 days after the second cycle of chemotherapy, and one month from the end of therapy. As most patients entered the study prior to general acceptance of the Deauville criteria (Biggi et al, 2013) , all PET/CT results were interpreted prospectively according to a previously published dynamic scoring system (Box S3).
Post hoc re-evaluation of PET/CT images using the Deauville system (Biggi et al, 2013) was performed centrally by a blinded reviewer in 343 (97%) patients. A score ≤3 was considered negative (Biggi et al, 2013) .
Patients were followed with physical examination and laboratory workup every 3 months during the first 24 months, every 4 months during the third year and biannually in years 4 and 5. From year 6, patients were evaluated annually. PET/ CT scans were performed every 6 months for 2 years and once during the third year .
Statistical methods
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for relapse were calculated for PET-2 scans in patients followed for at least 2 years after treatment initiation. Results were evaluated using intentionto-treat analysis. Kaplan-Meier methods were used to calculate PFS and OS. Cox regression analysis was used to calculate hazard ratios (HRs) with 95% confidence interval (CI) in the specified subgroups. At the study outset, the 3-year PFS of patients with positive PET-2 was estimated at 28%, based on a study by Gallamini et al (2014) which included 260 patients with early-HL and advanced-HL, of whom 45 (17%) were PET-2 positive. A sample size of 360 provides 83% power (with two-sided alpha = 0Á05) to detect a doubling of PFS to 56% (http://www.brixtonhealth.com/pe pi4windowsfunctionslist.html).
Two-tailed P-values of 0Á05 or less were considered statistically significant. Statistical analyses were performed using SPSS vers.21.0 for Windows (IBM Corp., Armonk, NY).
Safety
Cardio-respiratory toxicity was assessed using echocardiography performed at 1 and 3 years, and pulmonary function tests, including DLCO (lung diffusing capacity for carbon monoxide), performed 1 year after the end of therapy or earlier, if respiratory symptoms developed. Patients were questioned regarding menstrual regularity, pregnancy and childbirth. Second malignancies were recorded. The study was conducted in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice regulations.
Results
Three hundred and fifty-nine patients were enrolled in the study; three were withdrawn after pathological review assessed their tumours as non-Hodgkin lymphoma (Fig 2) . One additional patient was withdrawn for other reasons (subsection on "Safety"). Demographic and baseline disease characteristics of the 355 evaluable patients are presented in Table I .
Fifty (14%) patients experienced disease progression: 42 relapsed, eight had primary progressive disease. At a median follow-up of 55 (13-119) months, the estimated 5-year PFS for the whole group was 84% (95% CI 80-88). The 5-year OS at a median follow-up of 67Á5 (11Á5-131Á5) months was 98Á1% (95% CI 96Á5-99Á6). Seven patients died: one during autologous stem cell transplantation (SCT), two from a second relapse, two from complications of allogeneic SCT, one from acute myocardial ischaemia and one from cirrhosis after hepatitis B infection.
There were 170 patients with early-HL, of whom 20 (12%) had a positive PET-2. Nineteen (11%) experienced disease progression. In patients with positive PET-2, treatment was intensified with two additional ABVD cycles, followed by ISRT in 17. The 5-year PFS rates for the whole group, for patients with positive and negative PET-2 were 88Á7% (95% CI 83Á7-93Á7), 69Á2% (95% CI 48Á6-89Á8) and 91Á4% (95% CI 86Á7-96Á1), respectively. The difference between the 5-year PFS in patients with early HL and advanced disease with IPS 0-2 was not statistically significant (P = 0Á144). PFS was significantly worse in patients with positive versus negative PET-2 according to both dynamic and Deauville scores [HR 3Á69; 95% CI 1Á4-9Á7; P = 0Á008 and 7Á63 (95% CI 2Á7-21; P < 0Á000, respectively] (Figs 3A and 4; Table SI ). The 5-year OS for all, PET-2-negative and positive early-HL patients was 99Á4% (95% CI 98Á3-100Á6), 100% and 95% (95% CI 85Á4-104Á6), respectively.
Of 150 early-HL patients with negative PET-2, 87 (58%) did not undergo ISRT, including four with bulky mediastinal masses. The 5-year PFS for this subgroup was 93Á5 (95% CI 87Á9-99Á1). In patients with negative PET-2 who underwent ISRT the 5-year PFS was 88Á6 (95% CI 80Á7-96Á6). Patients with >3 disease sites were less likely to receive ISRT than those with fewer sites (odds ratio 0Á51; 95% CI 0Á27-0Á95; P < 0Á03). No differences in PFS were found in terms of patient age, gender, disease stage, bulk, or whether radiotherapy was administered (Table SII) .
Of 185 the 5-year PFS for the whole group, PET-2-negative and PET-2-positive subgroups was 79% (95% CI 72Á4-85Á5), 80Á8% (95% CI 74-87Á7) and 68Á4% (95% CI 49Á8-86Á9), respectively (P = 0Á07), with 5-year OS of 96Á8% (95% CI 94Á1-99Á6); 97Á8% (95% CI 95Á4-100Á3) and 91Á4% (95% CI 79Á9-102Á9) for all, PET-2-negative, and PET-2-positive subgroups, respectively (P = not significant; NS). HRs for relapse/progression or death comparing PET-2-positive and negative participants, based on dynamic and Deauville scores, were 2Á03 (95% CI 0Á92-4Á5; P = 0Á08) and 2Á79 (95% CI 1Á29-6Á03; P = 0Á009), respectively (Fig 4; Table SI ).
Among patients with IPS 0-2, relapse/progression occurred in 15% of PET-2-negative and 38% of PET-2-positive individuals [HR 2Á66 (95% CI 0Á97-7Á27); P = 0Á056]. The 5-year PFS for the whole group with IPS 0-2 was 77Á8% (95% CI 68Á9-86Á6) and in the subgroups with negative and positive PET-2 it was 80Á4% (95% CI 71Á3-89Á5) and 59% (95% CI 30Á8-87Á1), respectively. The 5-year OS for all patients with IPS 0-2 was 96Á9% (95% CI 93Á4-100Á4), 97Á6% (95% CI 94Á3-100Á9) and 92% (95% CI 77-107) for negative and positive PET-2, respectively (P = NS).
Among high-risk advanced-HL patients (IPS ≥3) initially treated with EB, the relapse/progression rate was 17% in PET-2 negative and 21% in PET-2 positive patients (P = NS). In 59 (80%) patients in this subgroup, therapy was de-escalated to ABVD. The 5-year PFS for the whole group with IPS 3-7 was 80Á8% (95% CI 70Á3-90Á3); it was 81Á5% (95% CI 71-92) for PET-2-negative and 78Á6% (95% CI 57Á1-100Á1) for PET-2-positive, respectively (P = NS), with corresponding OS of 96Á8% (95% CI 92Á4-101Á2), 98Á2% (95% CI 94Á6-101Á7) and 91Á3% (95% CI 75-107), respectively (P = NS) (Fig 3B-C) . No difference in PFS was found between patients with different IPS values, irrespective of age, gender or disease stage. Moreover, patients with IPS 0-2 and IPS ≥3 exhibited a similar percentage of negative PET-2 (88% and 81%, respectively; P = NS). Bulky disease did not impact on 5-year PFS; however, it was associated with referral for ISRT [10 (34%) vs. 14 (9%), P < 0Á001].
Interim PET/CT results and outcome prediction
Data on NPV, PPV for PET-2, therapy escalation or reduction are presented in Table II . These values do not reflect the true diagnostic value of interim PET, because treatment modifications occurred based the results of interim PET. Concordance was found between dynamic and Deauville scores in 93% of participants: sensitivity of 26% and 29%, specificity of 89% and 93%, PPV of 28% and 42% (P = 0Á23) and NPV of 87% and 88% (P = 0Á42) for dynamic and Deauville scores, respectively.
There were a total of 8 patients who demonstrated Deauville score 5 on PET-2; four of them relapsed. Three of these patients had early unfavourable disease, one of who had primary progressive disease despite therapy escalation to ABVD 36 + ISTR. Five of the 8 patients had advanced disease and three of them progressed (2/3 with IPS 0-2 and 1/2 with IPS ≥3).
Dose intensity
ABVD alone was given to 268 patients (75%) and 75 (21%) received ABVD 32-4 + EB 32-4, while only 12 patients (3%) received six EB cycles. Dose intensities of >90% were achieved for doxorubicin, vinblastine and dacarbazine in 96% and for bleomycin in 92% of patients treated with ABVD. In the groups receiving combinations of ABVD and EB or EB 36, dose intensities of >90% were achieved for cyclophosphamide and etoposide in 97% and 83%, for doxorubicin in 100% and 83%, and for bleomycin in 91% and 75%, respectively. 
Safety
Of 193 female participants, 159 were <40 years old, of whom 114 (72%) were evaluable for menstrual status. Ninety patients (78%) preserved or regained menstrual period, according to self-report, while 24 (22%) had premature ovarian failure (POF) during follow-up, with somewhat higher rates (33% vs. 20%) in those receiving any EB compared to ABVD only (P = 0Á52). Thirty-seven women (33 after ABVD and 4 after EB) became pregnant spontaneously and two underwent in vitro fertilization. Seven (1.9%) patients developed second malignancies. Single cases of lymphoblastic lymphoma, acute Ph+ lymphoblastic leukemia, papillary thyroid cancer, cutaneous B cell follicular lymphoma and breast cancer were observed. Secondary leukaemia was diagnosed in two patients, one had EB 32 + ABVD 34 and the other received one EB cycle and was then withdrawn from the study due to a suicidal attempt and drug abuse; he subsequently underwent multiple salvage therapies and succumbed to graft-versus-host disease after allogeneic SCT.
Non-fatal toxicity (persistent cough or shortness of breath) led to cessation of bleomycin in 25 patients after a median of 4 (1-5) chemotherapy cycles. Two patients required corticosteroid therapy, one of whom developed pneumocystis pneumonia. The mean DLCO (AEstandard deviation) decreased from 85Á5 AE 12Á6% to 78 AE 13% posttherapy (P < 0Á01).
Four patients had cardiac ischaemic events post-therapy, of which two occurred 4 years following mediastinal ISRT. Two other ischaemic events (one fatal) occurred in nonirradiated patients. One additional patient developed atrial fibrillation unrelated to RT. The mean left ventricular ejection fraction (AEstandard deviation) was unchanged preand one year post-therapy (64 AE 6% and 64 AE 7%, respectively).
Discussion
The current study was launched with the aim of finding a balance between maximizing the 5-year PFS while 
(C) Comparison between
Early-HL and Advanced-HL groups and between Advanced-HL subgroups. 5-year PFS for patients with early-HL versus advanced-HL (89% vs. 79%; P = 0Á056). 5-year PFS for patients with early HL versus advanced disease with IPS 0-2 (P = 0Á144). 5-year PFS for advanced-HL patients with IPS 0-2 vs. IPS ≥3 (78% and 81%, respectively; P = 0Á97). HL, Hodgkin lymphoma; IPS, International Prognostic Score; PET-2, positron emission tomography-computed tomography performed after two cycles of therapy; PFS, progression-free survival; RT, radiotherapy. minimizing the long-term toxicity associated with aggressive therapy (Engert et al, 2009; Behringer et al, 2010 Behringer et al, , 2013 Wongso et al, 2013) in HL. Both predefined prognostic factors and early change of therapy based on PET-2 results were applied to attain this goal.
In early-HL, the 5-year PFS was 91% vs. 69% for patients with negative versus positive PET-2. This confirms the poorer prognosis conferred by incomplete early response in patients treated with ABVD, suggesting the need for therapy escalation and not merely extension of the number of chemotherapy courses. Our results are in conformity with the Argentine Lymphoma Study Group trial evaluating the outcome of PET-3-adapted therapy, in non-bulky early-HL (Pavlovsky et al, 2016) .
Recently published data of EORTC trials (H10) demonstrated an increase in the 5-year PFS from 77% to 91% for supra-diaphragmatic early-HL and positive PET-2, observed with therapy escalation (Andr e, 2017). The U.S. Intergroup study (Cancer and Leukemia Group B/Alliance 50604) reported an estimated 3-year PFS of only 66% despite treatment escalation in patients with positive interim PET-CT (Straus et al, 2015) . At the current study outset, there was wide reported variability in the predictive value of a positive PET-2 (Moskowitz, 2015; Pavlovsky et al, 2016) and no consensus as to the need for therapy escalation.
While NPV of negative PET-2 in the early-HL group in the present study was 91%, 68% (13/19) of the total relapses occurred in this subgroup. The ongoing H16 trial by the GHSG (NCT00736320) will provide valuable information regarding further therapy for interim-PET-negative individuals.
Concern regarding long-term effects of RT has lately led to practice patterns forgoing radiation in early-HL. As a result, about 50% of young patients do not receive combined-modality therapy (Olszewski et al, 2015) . In the present study, the 5-year PFS and OS for PET-2-negative patients who did not receive ISRT were in line with previous studies using chemotherapy alone (Meyer et al, 2005; Canellos et al, 2010) .
Interim analysis of the H10 study (Raemaekers et al, 2014 ) demonstrated a superior PFS for patients receiving involved-nodal RT (INRT). In recently published final results, no significant difference in PFS was demonstrated between patients with EUF-HL and negative PET-2 who did or did not receive INRT (HR 1Á45 95% CI 0Á84-2Á5) (Andr e, 2017). The non-inferiority of the results observed in the arm not receiving INRT was refuted due to the broad 95% CI. In the RAPID trial, the per-protocol analysis showed a significant difference in PFS (90Á8% and 97Á1%) between PET-negative patients who received no further therapy following ABVD 33 and those who underwent RT (Radford et al, 2015) . Conversely, in the current study, the 3-year PFS of PET-2-negative patients, in whom ISRT was substituted with two additional ABVD cycles, was 95Á4% (95% CI 90Á1-99Á8). The discrepancies between these studies may be due to different metabolic cut-off points for PET-positivity, timing of interim PET (PET-3 versus PET-2), the age of enrolled patients, and the higher proportion of EUF patients receiving six ABVD cycles in our study. Results of various studies are presented in Figure S1 .
In advanced-HL, we chose EB as the initial therapy in patients with IPS ≥3 and escalation from ABVD to EB in those with positive PET-2, based on a large body of evidence of the poor prognosis conferred by interim PET-positivity (Hasenclever & Diehl, 1998; Gallamini et al, 2007 Gallamini et al, , 2014 Dann et al, 2012; Moccia et al, 2012 ). In the current study, this approach resulted in PET-2-negativity in 88% of patients with IPS 0-2 and 81% of patients with IPS 3-7 (OS 96Á9% and 96Á8%, respectively). The 5-year PFS for the whole group, PET-2-negative and PET-2-positive subgroups was 79%, 80Á8% and 68Á4%, respectively. These findings present the longest follow-up reported with this approach, and are in line with the 3-year PFS reported in the UK PET-2 adapted trials (Johnson et al, 2016; Zinzani et al, 2016) and S0816 (Friedberg et al, 2016) . These data are superior to those obtained in the studies using non- PET-2 adapted protocols, such as ABVD alone (Gordon et al, 2013) or the Stanford V regimen (Moccia et al, 2012) . (Figure S2 ) The 5-year OS in our study was remarkably similar to that reported when EB 36 was used ). Yet, in the present study, 81% of patients with IPS ≥3 initially receiving EB could have treatment de-escalation to ABVD following negative PET-2, resulting in only 6% of our advanced-HL cohort requiring EB 36. This is in conformity with the interim analysis of AHL2011, in which 12% of patients with advanced-HL had PET-2 positivity post-EB 32 (Casasnovas et al, 2015) . In the current study, patients with IPS 3-7 who initiated therapy with EB had outcomes similar to those with IPS 0-2, confirming the need for intensive therapy in patients with high IPS. Corroboration of these findings by the final results of ongoing large trials [e.g., the LYSA AHL-2011 (NCT01358747), the American Intergroup study S0816 (NCT00822120) and GITIL-0607 (NCT00795613)] is awaited. While none of the ongoing studies used IPS to stratify therapy, a sub-analysis of such data would be of interest.
The return of regular menses in the majority of our female advanced-HL participants may be attributed to minimal use of cumulative gonadotoxic chemotherapy (compared to trials of EB alone) and possibly concomitant use of GNRH agonists (Behringer et al, 2013) . Other toxicities were acceptable.
The strengths of the present study include multicentre participation and a relatively long and complete follow-up, while the sample size (355 patients), as well as its non-randomized design could be considered its weaknesses. The discretionary use of ISRT, although resulting in non-uniformity of treatment in early disease, actually paralleled the real-life approach to radiotherapy use in current practice (Olszewski et al, 2015) .
Conclusion
The individualized approach used in this study leads us to conclude that:
• PET-2 positivity at all HL stages is associated with an inferior prognosis. Additional courses of conventional chemotherapy in early-HL and therapy escalation in advanced-HL may be insufficient to overcome this negative effect.
• Stratification by IPS enables the choice of appropriate initial chemotherapy in advanced-HL.
• While the 5-year results of the current individualized approach appear promising with respect to PFS, OS and fertility preservation, only additional follow-up will determine whether this strategy will result in reduced long-term toxicity.
• Most relapses (numerically) occur in patients with negative PET-2; additional prognostic markers are required to identify HL patients at risk for disease progression despite negative PET-2.
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